BioSpace News Archive

The global pacemakers market size was valued at USD 3.4 billion in 2020, and is predicted to be worth around USD 6.01 billion by 2030, registering a CAGR of 3.6% during the forecast period 2022 to 2030.

The global surgical sphincteroplasty market size was valued at USD 2.3 billion in 2020, and is predicted to be worth around USD 5.67 billion by 2030, registering a CAGR of 6.8% during the forecast period 2022 to 2030.

Nitric oxide has witnessed increased demand owing to its rise in use in the medical sector and during the Covid-19 pandemic.

Advaxis, Inc., a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products announced the publication of results of their KEYNOTE-46 Phase 1/2 open-label, double-arm trial of ADXS-PSA with KEYTRUDA® in patients with metastatic, castration-resistant prostate cancer.

Ovid Therapeutics Inc. today announced that management will present at the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, at 12:45 p.m. ET.

Genetic Technologies Limited, a global leader in genomics-based tests in health, wellness and serious disease provides its year to date results for the nine months ended March 31, 2022.

Boundless Bio today will present a new finding at the American Association for Cancer Research (AACR) Annual Meeting.

Cybin Inc. today announced that the World Intellectual Property Organization (WIPO) published an international patent application covering a range of inhalation delivery methods across multiple psychedelic molecules (Patent Cooperation Treaty (PCT) patent application no.PCT/EP2021/07.

Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced that members of its management team will present a company overview and business update at the Needham Virtual Healthcare Conference on April 12, 2022 at 11:45 a.m. ET.

Kazia Therapeutics Limited, an oncology-focused drug development company, is pleased to announce new preclinical data demonstrating the activity of paxalisib in two forms of childhood brain cancer with very high unmet medical need.